Actinium Pharmaceuticals Inc
General ticker "ATNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $40.6M
Actinium Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -16.5%.
Estimated limits based on current volatility of 4.6%: low 1.16$, high 1.27$
Factors to consider:
- Current price 53.6% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.67$, 6.91$]
- 2024-12-30 to 2025-12-30 estimated range: [1.83$, 5.07$]
Short-term ATNM quotes
Long-term ATNM plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.14MM | $1.03MM | $0.08MM |
| Operating Expenses | $26.11MM | $35.13MM | $52.00MM |
| Operating Income | $-24.96MM | $-34.10MM | $-51.92MM |
| Non-Operating Income | $0.38MM | $2.17MM | $3.10MM |
| R&D Expense | $18.03MM | $23.14MM | $38.67MM |
| Income(Loss) | $-24.58MM | $-31.93MM | $-48.82MM |
| Profit(Loss) | $-24.58MM | $-31.93MM | $-48.82MM |
| Stockholders Equity | $73.55MM | $66.48MM | $36.38MM |
| Assets | $80.39MM | $114.19MM | $81.44MM |
| Operating Cash Flow | $-20.87MM | $8.64MM | $-47.34MM |
| Capital expenditure | $0.13MM | $0.37MM | $0.15MM |
| Investing Cash Flow | $-0.13MM | $-0.37MM | $-0.15MM |
| Financing Cash Flow | $35.22MM | $23.11MM | $14.87MM |
| Earnings Per Share* | $-1.20 | $-1.32 | $-1.83 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.